Development of malaria vaccines that block transmission of parasites by mosquito vectors

Journal of Medical Investigation

Volumn 49, Issue 3-4, 2002, Pages 118-123

  Hisaeda, Hajime ^a   Yasutomo, Koji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Malaria vaccine; P. vivax; P.falciparum; Transmission blocking vaccine

Indexed keywords

CHITINASE; MALARIA VACCINE; PROTEIN; PROTEIN PFS230; PROTEIN PFS25; PROTEIN PFS27; PROTEIN PFS28; PROTEIN PFS48; PROTEIN PVS25; PROTEIN PVS28; TRANSMISSION BLOCKING VACCINE; UNCLASSIFIED DRUG;

DEVELOPING COUNTRY; DISEASE CONTROL; DRUG MECHANISM; LIFE CYCLE; MALARIA; MOSQUITO; PARASITE DEVELOPMENT; PARASITE TRANSMISSION; PARASITE VECTOR; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTEIN EXPRESSION; REVIEW; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CULICIDAE; FEMALE; HOST-PARASITE RELATIONS; HUMANS; INSECT VECTORS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; REPRODUCTION; RODENTIA; SALIVARY GLANDS;

PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; TULIP BREAKING VIRUS;

EID: 0036704783     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. World Health Organization: World malaria situation in 1994. Wkly Epidemiol Rec 72: 285-292, 1997
2. HarinasutaT, Suntharasamai P, Viravan C: Chloroquine-resistant falciparum malaria in Thailand. Lancet 2: 657-660, 1965
3. Roberts DR, Ander RG: Insecticide resistance issues in vector-borne disease control. Am J Trop Med Hyg 50: 21-34, 1994
4. Nussenzweig RS, Vanderberg J, Most H, Orton C: Protective immunity produced by the infectio of x-irradiated sporozoites of Plasmodium berbhei. Nature 216: 160-162, 1967
5. Hoffman SL, Doolan DL: Malaria vaccines-targeting infected hepatocytes. Nat Med 6: 1218-1219, 2000
6. Good MF, Kaslow DC, Miller LH: Pathways and strategies for developing malaria blood-stage vaccine. Ann Rev Immunol 16: 57-87, 1998
7. Carter R, Mendis KN, Miller HL, Molineaux L, Saul A: Malaria transmission-blocking vaccines - How can their development be supported? Nat Med 6: 241-244, 2000
8. Williamson KC, Criscio MD, Kaslow DC: Cloning and expression of the gene for Plasmodium falciparum transission-blocking target antigen, Pfs230. Mol Biochem Parasitol 58: 355-358, 1993
9. Read D, Lensen AH, Begarnie S, Haley S, Raza A, Carter R: Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen pfs230 are all complement-fixing. Parasite Immunol 16: 511-519, 1994
10. Roeffen W, Geeraedts F, Eling W, Beckers P, Wizel B, Kumar N, Lensen T, Sauerwein R: Transmission blockade of Plasmodium falciparum malaria by anti-Pfs 230-specific antibodies is isotype dependent. Infect Immun 63: 467-471, 1995
11. Kocken CH, Jansen J, Kaan Am, Beckers PJ, Ponnudurai T, Kaslow DC, Konings RN, Schoenmakers JG: Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodiumfalciparum. Mol Biochem Parasitol 61: 59-68, 1993
12. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ, Stunnenberg HG, van Gemert GJ, Sauerwein RW, Eling W: A central role for P48/45 in malaria parasite male gamete fertility. Cell 104: 153-164, 2001
13. Roeffen W, Lensen T, Mulder B, Teelen K, Sauerwein R, van Druten J, Eling W, Meuwissen JH, Beckers PJ: A comparison of transmission-blocking activity with reactivity in a Plasmodiumfalciparum 48/45-kD molecule-specific competition enzyme-linked immunosorbent assay. AJ Trop Med Hyg 52: 60-65, 1995
14. Alano P, Premawansa W, Bruce MC, Carter R: A stage specific gene expressed at the onset of gametocytogenesis in Plasmodium falciparum. Mol Biochem Parasitol 46: 81-88, 1991
15. Lobo CA, Fujioka H, Aikawa M, Kumar N: Disruption of the Pfg27 locus by homologous recombination leads to loss of the sexual phenotype in P. falciparum. Mol Cell 3: 793-798, 1999
16. Ploton IN, Wizel B, Viscidi R, Kumar N: Mapping of two overlapping linear epitopes in Pfg27 recognized by Plasmodiumfalciparum transmission-blocking monoclonal antibodies. Vaccine 13: 1161-1169, 1995
17. Huber M, Cabib E, Miller LH: Malaria parasite chitinase and penetration of the mosquito peritrophic membrane. Proc Natl Acd Sci USA 88: 2807-2810, 1991
18. Shahabudding M, Toyoshima T, Aikawa M, Kaslow DC: Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease. Proc Natl Acd Sci USA 90: 4266-4270, 1993
19. Tsai YL, Hayward RE, Langer RC, Fidock DA, Vinetz JM: Disruption of Plasmodium falciparum chitinase markedly impairs parasite invasion of mosquito midgut. Infect Immun 69: 4048-4054, 2001
20. Langr RC, Vinetz JM: Plasmodium ookineter-secreted chitinase and parasite penetration of th mosquito peritrophic matrix. Trends Parasitol 17: 269-272, 2001
21. Kaslow DC, Quankyi IA, Syin C, Raum MB, Keister DB, Coligan JE, McCutchan TF, Miller LH: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333: 74-46, 1988
22. Kaslow DC, Bathurst IC, Lensen T, Ponnuduraoi T, Barr PJ, Keister DB: Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62: 5576-5580, 1994
23. Tsuboi T Kaslow DC, Gozar MMG, Tachibana M, Cao Y-M, Torii M: Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 4: 772-778, 1998
24. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC: Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68: 6618-6623, 2000
25. Sinden-Kiamos I, Vlachou D, Margos G, Beetsma A, Waters AP, Sinden R, Louis C: Distinct roles fo Pbs21 and Pbs25 in the in vitro ookinete to oocyst transformation of Plasmodium berghei. J Cell Sci 113: 3419-3426, 2000
26. Hisaeda H, Collins WE, Saul A, Stower AW: Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 dono show synergism. Vaccine 20: 763-770, 2001
27. Arevalo-Herrera M, Herrera S: Plasmodium vivax malaria vaccine development. Mol Immunol 38: 443-455, 2001
28. Kaslow DC, Quankyi IA, Keister DB: Minimal variation in a vaccine candidate from the sexual stage of Plasmodiumfalciparum. Mol Biochem Parasitol 32: 101-103, 1989
29. Lobo CA, Khar R, Kumar N: Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 67: 1688-1693, 1999.